In a meta-analysis of >6,000 patients with localized prostate cancer, prostate stereotactic body radiotherapy (SBRT) demonstrated favorable tumor control, patient-reported qualify of life (QOL), and toxicity. Researchers sought to systematically analyze biochemical recurrence-free survival (bRFS), physical-reported toxicity, and patient-reported outcomes following prostate SBRT. They found:

• 38 unique prospective series were identified involving 6,116 patients; median follow-up was 39 months across all patients.
• 92%, 78%, and 38% of studies included low, intermediate, and high-risk patients.
• Overall 5- and 7-year bRFS rates were 95.3% and 93.7%.
• Estimated late grade ≥3 genitourinary and gastrointestinal toxicity rates were 2.0% and 1.1%, respectively.
• By 2 years post-SBRT, EPIC urinary and bowel domain scores returned to baseline.